Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Folate receptor alpha (FRα) is a cell surface, glycosylphosphatidylinositol (GPI)-anchored glycoprotein that binds folate and reduced folic acid derivatives with high affinity. It mediates the delivery of 5-methyltetrahydrofolate and other folate analogs into cells, playing a crucial role in cellular uptake of folates. Due to its overexpression in many cancers and limited expression in normal tissues, it is a promising target for cancer therapy and diagnostics.
Various mechanisms depending on the targeting approach, including antibody-mediated cytotoxicity, drug delivery to cancer cells, and disruption of folate uptake.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Folate Receptor Alpha (FRα).